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The question of whether disinfection by-
products (DPBs) in drinking water pose any
health risk to humans has been an ongoing
issue since the discovery of DPBs in 1974.
Although toxicology experiments with indi-
vidual DPBs are necessary to establish plausi-
ble mechanisms of toxic action, epidemiologic
studies of human populations are necessary to
establish whether actual DPB exposures from
drinking water pose a human health risk.
Such studies have historically been focused on
cancer outcomes, but more recently a number
of studies have addressed the possibility of
adverse reproductive outcomes (1–12).
The ability of epidemiologic studies to
address these health questions has been seri-
ously limited by inadequate individual assess-
ment of exposure to DPBs (13,14). A major
prospect for improved exposure assessment
for epidemiologic studies of adverse repro-
ductive outcomes is to validate a biomarker
of exposure to DPBs. Desirable characteris-
tics of potential biomarkers of DPB exposure
have been discussed by Froese et al. (15).
To date, the only DPBs evaluated for use
as biomarkers of exposure have been the tri-
halomethanes (THMs) and the haloacetic
acids (HAAs). Weisel et al. (16) found that
most background breath samples from a
cohort of women who had participated in
the Klotz and Pyrch (8) study were nonde-
tectable for THMs in exhaled breath.
Measurable levels of THMs were obtained in
post-shower breath samples, and these
breath values correlated with water levels of
THMs. However, breath levels of THMs as
a biomarker of exposure to DPBs do not
persist for sufﬁcient time to integrate expo-
sure measurement over more than minutes
to hours, at most. Likewise, measurable
THM exposures are limited to inhalation
and dermal exposure from showering or
bathing. THM levels in breath will not
reflect ingestion exposure because of rapid
first-pass metabolism of ingested THMs in
the liver. THMs in blood were demon-
strated to be feasible for evaluating back-
ground THM exposure (17), but blood
sampling is an invasive procedure.
The potential of two HAAs, dichloroacetic
acid (DCAA) and trichloroacetic acid
(TCAA), as DPB biomarkers in urine was
examined with a cross-sectional study of a
cohort of 49 women, who provided 42 valid
samples (16,18). That study found that
DCAA was rapidly metabolized and that urine
levels showed no difference between low-expo-
sure and high-exposure groups. However,
TCAA did show higher excretion levels for
higher-TCAA-exposure versus lower-TCAA-
exposure groups. TCAA excretion in urine
did not correlate signiﬁcantly with measured
water concentrations of TCAA. A more
detailed TCAA exposure calculation was
done by accounting for the volume of water
consumed, the proportion of heated water
used (estimating a 39% reduction in TCAA
from boiling), and the use of home water ﬁl-
ters (estimating a 70% reduction for any ﬁl-
ter type). With these adjustments, a
signiﬁcant correlation (R of 0.73, n = 42) was
found between estimated TCAA ingestion
(estimated as micrograms of TCAA con-
sumed in the previous 48 hr) and measured
TCAA excretion rate (ng/min). Given these
promising results, we undertook a pilot trial
to examine the viability of TCAA in urine as
a biomarker of DPB ingestion exposure.
The promise of urinary TCAA as a bio-
marker for drinking water ingestion expo-
sure needs to be evaluated in a longitudinal
pilot study to address the temporal relation-
ship between ingestion exposure and urinary
excretion. A pilot evaluation of TCAA as a
biomarker needs to characterize both
interindividual and intraindividual variabil-
ity of TCAA ingestion and urinary excre-
tion, determine the persistence of TCAA
excretion following ingestion (as measured
by the half-life of urinary TCAA excretion),
and evaluate the feasibility of TCAA in ﬁrst
morning urine (FMU) samples for potential
use in future epidemiology studies. 
We designed a pilot exposure/interven-
tion study of approximately 5 weeks’ dura-
tion to provide some insight on these issues
and to guide future studies.
Methods
Water supply system. Overall, the Adelaide,
South Australia, metropolitan region has six
major supply zones for six treatment plants,
each drawing water from a particular reser-
voir. Because the reservoirs are affected by
different watershed characteristics, the dis-
solved organic carbon levels of the water
differ considerably as well, leading ultimately
to quite different DPB concentrations and
profiles among the communities in and
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We addressed the need for a biomarker of ingestion exposure to drinking water disinfection by-
products by performing a human exposure trial. We evaluated urinary excretion of trichloroacetic
acid (TCAA) as an exposure biomarker using 10 volunteers who normally consume their domes-
tic tap water. We recruited the volunteers at a water quality research laboratory in Adelaide,
Australia. Participants maintained a detailed consumption and exposure diary over the 5-week
study. We also analyzed tap water and first morning urine (FMU) samples for TCAA, and tap
water for chloral hydrate (CH). We documented both interindividual and intraindividual variabil-
ity in TCAA ingestion and urinary excretion, and both were substantial. With a TCAA-free bot-
tled water intervention, we used creatinine-adjusted urinary TCAA levels to estimate urinary
TCAA excretion half-lives for three of the participants. We observed correspondence over time
between estimated TCAA excretion, calculated from TCAA + CH ingestion levels, and measured
TCAA urinary excretion. This study demonstrates the merits and feasibility of using TCAA in
FMU as an exposure biomarker, and reveals remaining concerns about possible alternate sources
of TCAA exposure for individuals with low drinking water ingestion exposure. Key words: disin-
fection by-products, drinking water, exposure assessment, haloacetic acids, trichloroacetic acid.
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acteristics of the four major water supply
zones we ultimately selected.
Recruitment of study cohort. We solicited
healthy adult volunteers from the Australian
Water Quality Centre (AWQC), with the
intent to recruit at least two or three partici-
pants from each of the four water supply sys-
tems we selected. We recruited a cohort of 10
volunteers, consisting of eight males and two
females with ages ranging from 24 to 57
years. We expected that this cohort, associ-
ated with the AWQC, would be motivated
to contribute to our research findings by
cooperating with the demands of the 
study. The Monash University Standing
Committee on Ethics in Research Involving
Humans approved the study protocol, and
we obtained written informed consent from
participants at enrollment.
Study design. During the summer sea-
son in Adelaide (February 2000), we moni-
tored participants via consumption diaries
and with tap water and urine analyses for
an initial period in which they consumed
water from their normal tap water supply
containing variable levels of TCAA, an
intervention period with consumption of
DPB-free bottled water, followed by a ﬁnal
return to normal tap water consumption
(Table 2).
We classified daily fluid consumption
according to cold and hot tap water and
“other,” with specific locations or regional
locations for all ﬂuid consumption. Hot tap
water included all beverages, such as coffee
and tea, that were prepared using boiled
water. “Other” beverages included bottled
juices, soft drinks, alcoholic beverages, and
the like. Additionally, we tracked other water
exposures, including showering/bathing,
washing dishes, washing cars, swimming/hot
tub use, and so on. We asked participants 
to document potential exposures to
trichloroethylene (TCE) and trichloroethane
from visits to dry cleaning establishments,
wearing dry-cleaned clothing, or exposure to
these solvents in the AWQC laboratory.
Participants started the diaries 48 hr before
the ﬁrst urine sample collection.
Participants brought entire FMU voids
and home tap water samples to the AWQC.
If the participant anticipated a delay of more
than 4 hr before the sample could be deliv-
ered to the lab, he or she stored the sample in
a cooler with ice or in a refrigerator. We gen-
erally extracted samples for analyses within 6
hr of collection, and performed the study.
Analytical methodology. We performed
analysis of TCAA in urine according to a
modified version of U.S. Environmental
Protection Agency (EPA) method 552.2 (19)
and the method used by Kim and Weisel
(20). We measured an aliquot of urine (40
mL) into a graduated cylinder and poured it
into a 50-mL centrifuge tube. We added a
surrogate standard comprised of 80 µL of a
25 µg/mL solution of 2,2-dichloropropionic
acid and acidiﬁed the sample using 2 mL of
concentrated sulfuric acid. We added approx-
imately 12 g of sodium sulfate and 4 mL of
methyl tert-butyl ether (MTBE) containing
approximately 500 µg/L (known concentra-
tion) of 1,2,3-trichloropropane as an internal
standard. We hand-shook the samples for 8
min to ensure that the sulfate salt fully satu-
rated the samples, and we then centrifuged
them at 2,500 rpm for 15 min.
Using a Pasteur pipette, we transferred the
entire solvent layer to a 10-mL glass vial,
added 3 mL of acidified methanol (10%
H2SO4 in methanol), and then vortexed it for
30 sec and placed it in a 50°C heating block
for 1 hr. We then added 8 mL of saturated
NaHCO3 solution to the vial, after removing
it from the heating block, to neutralize the
acid. We added the NaHCO3 solution drop-
wise to avoid sputtering and solvent loss. We
then transferred the solvent layer to and eluted
it through a disposable activated-carbon solid-
phase extraction (SPE) column (6 mL × 250
mg; Envi-Carb, Supelco, Sigma-Aldrich
Canada Ltd., Oakville, ON, Canada) to
reduce the organic background, as indicated
by extracted color. We collected the SPE col-
umn eluate in a 2-mL autosampler vial.
We prepared tap water samples and ana-
lyzed them for HAAs in the same manner as
the urine samples, with the exception that
we omitted the Envi-Carb SPE step. 
We analyzed the samples on a Varian
3400 gas chromatograph (GC) with a single
injection (run in splitless mode) leading into
two analytical capillary columns, each with an
electron capture detector (ECD). The simul-
taneous dual column analysis [DB-1, 30 m ×
0.25 mm internal diameter (i.d.), 0.25 µm
ﬁlm; DB-1701, 30 m × 25 mm i.d., 0.25 µm
film] allowed for confirmation of analyte
peaks. We calibrated the GC-ECD with a
mixture of methyl ester HAAs. The calibra-
tion range was ≤ 0.1–50 µg/L for TCAA.
These methods provided excellent perfor-
mance [relative standard deviation (RSD) of
4.8% on 11 triplicate analyses of tap water
and 8.5% on 17 triplicate analyses of urine]
and allowed sensitive detection of TCAA in
urine. Our method detection limit (MDL)
for these analyses was approximately 0.2 µg/L
for tap water and 0.3 µg/L for urine, based on
three times the SD for triplicate sample analy-
ses, averaged for triplicate sets with TCAA ≤ 2
µg/L. The mean surrogate recovery for 384
analyses was 119% (median, 118%; SD,
31%); we corrected all TCAA values for
recovery. We selected two urine samples at
random on day 13 of the study and tested
them for storage loss over 72 hr. The average
absolute reduction in TCAA concentration as
measured was 0.16 µg/L, or 12%. With the
average SD of analyses done at this concentra-
tion level at 0.1 µg/L, and the fact that we
analyzed the vast majority of the samples on
the day we received them, we judged the loss
of TCAA over 72 hr to be inconsequential for
the purposes of this study.
We analyzed tap water samples for chloral
hydrate (CH) using the AWQC standard test
method TMS-003 (21), which is based on
U.S. EPA method 551 (22). Brieﬂy, we trans-
ferred 35 mL of tap water (collected with zero
headspace and quenched with NH4Cl) to a
glass vial, added Na2SO4, and extracted the
samples using 2 mL of MTBE containing
dibromopropane as an internal standard. We
transferred sample extracts directly to 2-mL
autosampler vials and analyzed them on the
Varian 3400 system described above.
Results and Discussion
Tap water ingestion. We easily detected
TCAA in all FMU samples that we analyzed,
even though most of the tap water TCAA
exposure levels were lower than expected
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Table 1. Characteristics of drinking water supply zones used in the study.
Anstey Hill Little Para Happy Valley Hope Valley
Study participants AD1–AD4 AD5 AD6–AD8 AD9, AD10
Source water to River Murray Little Para  Onkaparinga  Torrens
supply reservoir and Torrens system and  system and River  system and
system River Murray Murray River Murray
Approximate average 2 months 3 months 1 month 20 days
water residence time in
reservoir
Free chlorine residual 1.3 mg/L 1.2 mg/L 1.5 mg/L 1.2 mg/L
All plants use the following water treatment processes: alum coagulation, ﬂocculation, lime, anthracite-sand rapid ﬁltration,
chlorination. All plants are capable of dosing powdered activated carbon when required, and prechlorination prior to coag-
ulation and ﬁltration when required. Anstey Hill and Little Para are capable of caustic addition prior to coagulation. Use of
River Murray is directly dependent on rainfall for the year and varies from 40% to 90% of total water supply to reservoirs.
Table 2. Experimental design for TCAA exposure
and intervention study.
Water FMU sample No. FMU
Week source days samples
1 Regular tap Tues 1
2 Regular tap Mon–Fri 5
3 Bottled Mon–Sun 7
4 Bottled None 0
5 Regular tap Mon, Wed, Fri 3based on our study planning surveys.
Relatively low TCAA ingestion exposures
occurred for most participants. Detectability
of TCAA in urine fulfills an important
requirement for the feasibility of an exposure
biomarker (15).
Figure 1 plots the temporal trends
throughout the study period for participant
AD2 showing the daily TCAA ingested
(TCAAin) and TCAA excreted (TCAAex).
The lines connecting data points are for
visualization purposes only. We examined
the initial exposure phase (tap water expo-
sure) of the study separately to examine pos-
sible relationships between TCAAex and
TCAAin and response variability, both inter-
and intraindividual. For this aspect of the
data analysis, we used data collected up to
and including 13 February 2000 (and the
FMU of 14 February 2000).
Table 3 provides a summary of results for
TCAAin and TCAAex showing the intraindi-
vidual variability. We calculated TCAAin
from the volumes of cold tap water and hot
beverages consumed at the participants’
homes, work, and other locations and the
TCAA concentrations as measured in cold
tap water at the participants’ homes and at
the AWQC. If participants consumed tap
water or hot beverages at other locations, we
speciﬁed the town or subdivision to match an
approximate TCAA value for those locations
where we did not take samples directly. For
the hot beverages, we estimated a 35% reduc-
tion of TCAA relative to location-speciﬁc tap
water to determine external exposure due to
this portion of fluid intake. We based this
adjustment on our observed reduction in
TCAA for water boiled for 3 min, and it is
reasonably consistent with the approach used
by Weisel et al. (16). However, we classiﬁed
at least one-third of total fluid intake as
“other,” to which we can assign no TCAA
exposure contribution. Because this propor-
tion of ﬂuid intake is so large, the potential
for additional TCAA ingestion exposures to
be unaccounted for is also substantial.
We calculated the TCAAex values from
the measured TCAA concentrations in the
urine samples, the volume of sample, and the
reported time from the last previous urina-
tion to the FMU. We linearly extrapolated
the hourly TCAA excretion rate for the FMU
to 24 hr to estimate the daily TCAAex. Also,
because the FMU samples correspond to the
water consumed in the 24 hr before sam-
pling, we adjusted the date of TCAAex back 1
day to correspond to the TCAAin date.
Ultimately, we defined the consumption
period before sampling that affects urinary
TCAA concentration by the excretion half-
life relationship for that individual. Equation
1 (below) considers this deﬁnition, but for an
initial comparison we adjusted TCAAex to
align with TCAAin 1 day earlier to account
for the ingestion that corresponds to the
main source of the excretion for that day.
For ingestion variability, Table 3 shows
that the RSD for TCAAin among the 10 par-
ticipants over the 12 days of tap water inges-
tion ranges from a low of 14% to a high of
67%. The low value corresponded to a low
average TCAAin (mean of 5.2 µg/day) com-
pared with much higher average TCAAin for
the high RSD (41 and 53 µg/day). Average
TCAAin was bimodally distributed among
the 10 participants, with three participants
(Anstey Hill system) having mean TCAAin
ranging from 41 to 73 µg/d. The other seven
participants had more than 10-fold lower
mean TCAAin, ranging from 2.3 to 7.9 µg/d.
We calculated TCAAin from TCAA con-
centrations in consumed tap water and the
volume consumed; therefore, the variability
will depend on the variabilities of a) TCAA
in water, which is related to the tap water
location and sampling day, and b) volume(s)
of different source waters consumed. For
TCAA in water, Table 4 provides an
overview of how TCAA in water varied over
time and location for the tap water period of
the study. TCAA concentration averages for
each participant’s home tap water ranged
from 1.8 µg/L to 29 µg/L, with an average
RSD of 39% over the time studied. We
observed much greater variation spatially for
each tap water day, with TCAA concentra-
tions averaging from 7.7 to 20 µg/L for any
particular day, but the RSD averaged 100%.
The diverse distribution network in the
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Figure 1. Temporal trends of TCAAin and TCAAex for AD2.
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Table 3. Intraindividual variability of TCAA ingestion and excretion during 12 days of tap water ingestion
(TCAA excretion estimates are based on hourly excretion rate for FMU linearly extrapolated to full 24 hr).
Water Mean ± SD RSD Minimum Maximum
Participant system TCAA (µg/day) (%) (µg/day) (µg/day)
AD1 Anstey Hill Ingestion 41 ± 27 67 3.9 94
Excretion 5.2 ± 3.7 71 1.9 12
AD2 Anstey Hill Ingestion 73 ± 47 64 24 150
Excretion 24 ± 73 1 1 6 3 8
AD3 Anstey Hill  Ingestion 7.9 ± 2.6 34 5.9 14
Excretion 1.5 ± 0.80 53 0.8 2.7
AD 4 Anstey Hill  Ingestion 53 ± 35 67 12 120
Excretion 5.8 ± 2.3 40 2.6 9.2
AD5 Little Para Ingestion 3.4 ± 1.2 35 1.3 5.7
Excretion 3.1 ± 2.0 63 1.5 7.0
AD6 Happy Valley Ingestion 5.6 ± 3.1 55 2.0 11
Excretion 4.7 ± 0.69 15 3.9 5.7
AD7 Happy Valley Ingestion 2.3 ± 1.3 55 1.0 5.1
Excretion 2.4 ± 0.95 39 1.3 4.2
AD8 Happy Valley Ingestion 3.6 ± 1.2 32 1.4 5.3
Excretion 3.3 ± 2.1 64 1.8 7.5
AD9 Hope Valley Ingestion 19 ± 8.6 45 4.4 32
Excretion 4.6 ± 3.2 69 1.3 11
AD10 Hope Valley Ingestion 5.3 ± 0.76 14 4.3 6.1
Excretion 4.7 ± 2.25 47 2.0 7.1greater Adelaide area, with its distinct water
reservoirs for different subdivisions, has a
major impact on the overall variability of the
TCAA concentrations.
The other major contributors to inges-
tion variability were the volume of water con-
sumed and the specific category of fluid
consumed. The variability increases when the
relative proportion of water from different
categories changes. Participants recorded
their water consumption under the categories
of cold or hot water (under “hot” we
assumed coffee or tea beverages), with subcat-
egories for location of consumption: home,
work, or other (suburb or location speciﬁed).
A ﬁnal category of “other” included all other
beverages—juices, soft drinks, beer, wine,
and so on. For this last category, because we
did not measure TCAA concentrations, we
cannot estimate TCAA exposure amount.
We averaged reported consumption amounts
for each beverage category over the tap water
days for each individual (Table 5). We used
these individual averages to determine an
overall interindividual variability for the 12
days of tap water consumption before begin-
ning the bottled water intervention. The
average RSD ranged from 48% to 200%.
Table 5 results show that individuals had
RSDs of about 30–300% for any particular
category of water consumption (volume) over
the 12 tap water days of the study, clearly
indicating that consistent day-to-day tap
water consumption volumes cannot be
assumed. This ﬁnding raises a caution about
the validity of retrospective questionnaires
used to reconstruct the consumption patterns
over extended periods by depending on the
recall of study participants.
The variability of TCAAin for AD2, for
example, was caused partly by variation of
TCAA in the home tap water; however, it was
also largely caused by this participant con-
suming as little as 0.6 L to as much as 3 L of
tap water at home, with the remainder of
ﬂuid consumption classiﬁed as “other.” Daily
home consumption of tap water showed a
variation for this individual of 48% (RSD),
whereas total fluid consumption for these
days varied only 25%. Other individuals
showed more diverse variability because they
consumed cold tap water and heated bever-
ages at home and in the workplace, in addi-
tion to “other,” whereas AD2 recorded only
home tap water and “other.”
We gained additional insight by calculat-
ing and comparing the ratios of tap water or
beverages consumed relative to total liquids
ingested (Table 5). Overall, we found that
cold tap water consumption at home
accounts for 39 ± 17% of total consumption
and at work accounts for 7 ± 9% of total
consumption. These water sources were the
best characterized in this study, because we
had several tap water samples from each
location. Of the remaining consumption cat-
egories, the major contributors to total con-
sumption were hot beverages consumed at
home (10 ± 6%) and “other” (34 ± 17%).
For excretion variability, the RSD of
TCAAex ranged from a low of 15% to a high
of 71%, with a median of about 47% (Table
3). For excretion, only one participant (AD2)
had a high average TCAAex at 24 µg/d. The
other nine participants had an average
TCAAex ranging from 2.4 to 5.8 µg/d.
Overall, these results indicate substantial
interindividual variability in both daily TCAA
ingestion and excretion rates. The only other
published study evaluating TCAA as a bio-
marker of drinking water DPBs was a cross-
sectional design (16,18). When urine samples
and tap water samples are collected at the
same time in a cross-sectional approach, the
influence of daily variations and ingestion
from previous days cannot be corrected. For
exposure assessment from a urine sample and
a water sample taken at the same time, if
excretion half-lives are a matter of days, water
concentrations must remain constant for sev-
eral days before the sampling if we expect a
meaningful evaluation of validity.
Figure 2 shows that both inter- and
intraindividual variability were substantial.
The error bars represent ±1 SD for the mea-
surements. Figure 2 shows the variability in
TCAAex compared with TCAA concentration
in the tap water consumed. One participant
on the Anstey Hill system (AD2) stood well
apart from the rest in terms of TCAAex. Two
others, AD1 and AD4, had relatively high
TCAA levels in their tap water, but their
TCAAex was substantially less than AD2, in
part because of a lower level of tap water
consumption. In all cases, however, the data
in Figure 2 illustrate the large variability in
both tap water TCAA exposure concentra-
tions and excretion of TCAA for all partici-
pants. Faced with such variability, a
cross-sectional sampling scheme would pro-
vide only a limited basis to evaluate and
account for interindividual variability, and
no basis to evaluate or account for intraindi-
vidual variability of urinary TCAA.
We consistently found the highest tap
water ingestion exposures in the Anstey
Hill system (participants AD1–AD4). In
this distribution system, we observed sub-
stantial daily variation of the TCAA con-
centrations in tap water at each of the
homes of the four participants (Table 4),
making questionable any assumption of
consistent water quality from day to day.
The variation from location to location,
most noticeable between AD3 and the
three other participants in the Anstey Hill
system, also shows the difﬁculty of general-
izing exposures on the basis of assumptions
about consistent water quality at different
distribution system locations served by the
same treatment plant source.
To evaluate further the interindividual
variability for those who were most substan-
tially exposed to TCAA ingestion via tap
water exposure, we analyzed the differences
among the Anstey Hill participants
AD1–AD4 (Table 6). These data show that
daily RSD among those four participants
served by the same treatment plant ranged
from 54% to 100% for TCAAin and from
54% to 150% for TCAAex.
CH, which has been used extensively as
an anesthetic in clinical practice, is metabo-
lized to TCAA (23). Consequently, we mea-
sured CH in the tap water throughout the
study, and it appears to have a variable rela-
tionship with TCAAin or TCAAex; that is,
CH did not correlate well with TCAA in
water, nor did it correlate signiﬁcantly with
urinary TCAA. However, we considered
the contribution of CH to TCAAex in
accounting for the total potential for uri-
nary TCAAex, to evaluate the correspon-
dence of excretion with ingestion as well as
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Table 4. Variability in tap water TCAA (µg/L) for different homes, distribution systems, and sample dates.
Little 
Anstey Hill Para Happy Valley Hope Valley RSD
Date AD1 AD2 AD3 AD4 AD5 AD6 AD7 AD8 AD9 AD10 Mean ± SD (%)
1 Feb 47 49 5.1 52 2.6 5.1 3.4 4.3 10 NA 20 ± 22 110
7 Feb 35 41 7.5 39 2.2 3.1 2.5 4.1 25 3.3 16 ± 17 100
8 Feb 43 42 16 39 2.0 3.1 2.1 3.8 NA 3.1 17 ± 19 110
9 Feb 25 22 9.4 26 1.2 NA 1.6 2.5 17 2.2 12 ± 11 90
10 Feb 26 19 11 22 1.1 2.0 1.7 2.9 NA 1.7 9.7 ± 10 110
11 Feb 16 17 5.8 17 1.2 1.4 1.3 2.3 NA NA 7.7 ± 7.5 97
14 Feb 17 18 6.4 19 1.5 2.0 1.9 2.2 15 2.3 8.5 ± 7.6 90
28 Feb 16 22 2.4 13 1.7 2.4 2.6 2.1 11 3.3 7.7 ±7.3  95
1 Mar 28 29 1.5 26 2.5 2.8 3.0 3.8 5.7 4.7 11 ± 12 110
3 Mar 32 34 NA 29 1.9 3.4 3.0 3.5 NA NA 15 ± 13 100
Mean 28 29 7.2 28 1.8 2.8 2.3 3.1 14 2.9 100
SD 11 11 4.5 12 0.5 1.1 0.7 0.8 6.6 1.0
RSD (%) 39 39 62 42 30 38 30 27 48 33 39
NA, not analyzed. Temporal variability for each site is indicated in the lower rows by average value for the days sampled
and the relative percentage deviation. Spatial variability across sites for each day sampled is represented in the right-
hand columns by the average value and the relative percentage deviation.the proportion of potential TCAAex that we
actually observed.
Bottled water intervention. In the third
week of the exposure study, we asked partici-
pants to switch to DPB-free bottled water for
all hot and cold water ingestion. We made
bottled water and a dedicated kettle available
in the workplace cafeteria so that boiled
beverages could be prepared using the DPB-
free water. In the time-trend plots in Figure 1,
the decrease in TCAAex can be seen to lag the
introduction of bottled water by a few days.
Elimination half-life estimation. There
has been limited research directly on the
pharmacokinetics of TCAA excretion, with
most of the literature focused on TCAA as 
a metabolite of either CH or TCE.
Elimination half-life estimates for plasma
TCAA ranged from 70 hr (2.9 days) to 120
hr (5 days) based on oral ingestion of
6.25–40 mg/kg CH (24,25). These CH
doses correspond to levels 2,000 to more
than 10,000 times higher than realistic
TCAA drinking water exposure levels.
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Table 5. Average volumes and relative ratios of ﬂuids from each category and location from participant consumption journals.
Volumes of ﬂuids consumed in each category and location (mL) Ratios of beverages consumed to total volume
Category Cold Hot Cold (totals %) Hot (totals %) Other 
location Home Work Other Home Work Other Other Total Home Work Other Home Work Other total (%)
AD1
Mean 975 0 400 0 0 75 1,700 3,150 31 0 13 0 0 2 54
SD 575 0 550 0 0 125 725 761 18 0 17 0 0 4 23
RSD (%) 59 140 170 43 24
n 10 10 10 10 10 10 10 10
AD2
Mean 2,150 0 0 0 0 0 1,400 3,550 61 0 0 0 0 0 39
SD 1,050 0 0 0 0 0 300 900 30 0 0 0 0 0 8
RSD (%) 49 21 25
n 10 10 10 10 10 10 10 10
AD3
Mean 950 350 0 100 325 0 800 2,500 38 14 0 4 13 0 32
SD 375 325 0 125 325 0 175 300 15 13 5 13 0 7
RSD (%) 39 93 130 100 22 12
n 10 10 10 10 10 10 10 10
AD4
Mean 1,000 600 0 475 275 0 575 2,900 34 21 0 16 9 0 20
SD 525 550 0 300 250 0 150 275 18 19 0 10 9 0 5
RSD (%) 53 92 63 91 26 9
n 10 10 10 10 10 10 10 10
AD5
Mean 1,150 200 0 425 225 0 500 2,500 46 8 0 17 9 0 20
SD 500 250 0 225 225 0 475 575 20 10 0 9 9 0 19
RSD (%) 43 130 53 100 95 23
n 10 10 10 10 10 10 10 10
AD6
Mean 1,400 300 50 0 25 0 575 2,350 60 13 2 0 1 0 24
SD 400 425 100 0 75 0 375 575 17 18 4 0 3 0 16
RSD (%) 29 140 200 300 65 24
n 10 10 10 10 10 10 10 10
AD7
Mean 400 10 25 350 350 150 393 1,650 24 1 2 21 21 9 24
SD 200 25 50 200 375 350 287 300 12 2 3 12 23 21 17
RSD (%) 50 250 200 57 107 233 73 18
n 10 10 10 10 10 10 10 10
AD8
Mean 350 100 25 225 200 0 875 2,025 17 5 1 11 10 0 43
SD 275 125 50 150 200 0 575 600 14 6 2 7 10 0 28
RSD (%) 79 130 200 67 100 66 30
n 10 10 10 10 10 10 10 10
AD9
Mean 525 275 175 425 150 125 1,350 2,925 18 9 6 15 5 4 46
SD 400 350 375 475 200 150 350 625 14 12 13 16 7 5 12
RSD (%) 76 130 210 110 130 120 26 21
n 10 10 10 10 10 10 10 10
AD10
Mean 1,550 175 0 450 200 0 1,225 3,500 44 5 0 13 6 0 35
SD 275 475 0 150 225 0 1075 925 8 14 0 4 6 0 31
RSD (%) 18 270 33 110 88 26
n 777 577 77
Average 1,050 200 75 250 175 25 950 2,700 37 8 2 10 7 2 34
Mean SD 450 250 125 175 200 75 450 575 17 9 4 6 8 3 17
Interindividual 
RSD (%) 43 125 170 70 110 300 47 21 44 120 170 66 110 190 49
n = Number of days of tap water exposure for which ingestion data is available. Each participant recorded ingested ﬂuid volumes on daily journal sheets and provided those sheets with
each FMU and tap water sample. Volumes were recorded to the nearest 25 mL. All calculations given in this table were derived from these data and have been rerounded to the nearest
25 mL. Volume averages, SD, and RSD are listed for each individual in the left-hand section of the table and indicate intraindividual variation over the 10 days of tap water consumption.
At the bottom of this section, overall averages and SDs indicate interindividual variability across all 10 participants for this study period. These numbers are derived from the individual
averages and the individual SD values. For each participant, ratios of average volumes in each category and location versus the average total consumption volume are provided in the
right-hand section. Below each average percentage contribution to the total is the ratio of the SD to the average total volume; therefore, the relative proportion of the various categories
and locations of ﬂuids consumed can be written as, for example, 31 ± 18%.Bruning et al. (25) quote an elimination
half-life of 100 hr (4.2 days) for TCAA as a
metabolite of TCE, but they do not provide
any experimental details or any reference
citation. Muller et al. (26,27) reported an
elimination half-life of 50.5 hr (2.1 days) for
an oral dose of 3 mg/kg of TCAA. Much
earlier, Paykoc and Powell (28) reported
TCAA experiments for which Schultz (29)
has calculated elimination half-lives of 99 hr
(4.1 days), 76 hr (3.2 days), and 74 hr (3.1
days) for three volunteers given intravenous
injection doses of 37.3, 60.2, and 28.1
mg/kg of TCAA, respectively. These doses
are ≥ 10,000 times higher than realistic
TCAA drinking water exposure levels.
Because most of the tap water exposures
to TCAA were lower than expected in this
pilot study, only three participants (AD1,
AD2, AD6) provided results that were useful
for estimation of TCAA urinary elimination
half-life (t1/2). In each case, we divided the
TCAA concentration measured in FMU sam-
ples by the creatinine concentration for these
samples to correct for variations in FMU vol-
ume. We plotted this creatinine-normalized
TCAA concentration (µg TCAA/g creatinine)
against time in days, with time zero (13
February) being the start of the bottled water
intervention. We evaluated the logarithm of
the creatinine-normalized TCAA urinary
excretion for a linear ﬁt against time (corre-
sponding to an exponential decay). Figure 3
shows the urinary TCAA die-off curve for
AD1, suggesting an elimination half-life of
3.67 day. This data set is not extremely con-
vincing, with an R2 of only 0.45. The poor ﬁt
is mainly caused by the high value for day 1,
which was suspiciously high in TCAA and
low in creatinine relative to urinary volume.
We have chosen to leave this point in the
analysis with the foregoing qualiﬁer, acknowl-
edging the poor quality of ﬁt.
Figure 4 shows the urinary TCAA die-off
curve for AD2, the highest exposed
participant, suggesting an elimination half-life
of 2.3 days. This data set is more convincing,
with an R2 of 0.74 for the exponential decay
curve. Finally, Figure 5 shows the urinary
TCAA die-off curve for AD6, suggesting an
elimination half-life of 2.9 days and an R2 of
0.70 for the exponential decay curve.
Although the number of data points for each
of these curves is limited, these data are the
ﬁrst reported for TCAA elimination half-life
measured for TCAA concentrations low
enough to be relevant to drinking water expo-
sure and for TCAA administered by drinking
water ingestion. The values observed are fully
consistent with the few human values
reported in the literature for high exposure
and metabolite-generated TCAA elimination
volunteer studies. This consistency suggests
that urinary TCAA elimination is not likely
to be saturated by any plausibly high level of
TCAA exposure via drinking water.
Correspondence of excretion with inges-
tion. The longitudinal design of our study
also allowed us to explore, albeit with limited
numbers of data points, whether there is any
correspondence between ingestion and excre-
tion of TCAA. Ultimately, confidence in a
relationship between ingestion and excretion
must be established for urinary TCAA to pro-
vide any value for DPB exposure assessment.
We limited the evaluation of individuals
over time to those who provided reasonable
data on elimination half-life. We made this
choice because we needed to account for the
inﬂuence of prior exposure carrying over to
observed excretion. The deﬁnition of urinary
elimination half-life, (e.g., 2–3 days) means
that after this time period only half of a batch
of TCAA ingested will have been excreted.
After two half-lives have passed, up to 25%
of the total available excretion from the prior
exposure would still contribute toward excre-
tion on the subsequent day. We used a run-
ning average of ingestion that accounts for
TCAA + CH ingested on previous days,
adjusted according to the exponential die-off,
to generate a calculated upper bound to
TCAA excretion (assuming 100% of ingested
CH is metabolized to TCAA and all internal
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Table 6. Interindividual variability during 12 days of tap water TCAA ingestion—Anstey Hill water distribu-
tion system (participants AD1–AD4).
Mean TCAA ± SD RSD  Minimum Maximum
Date Type (µg/day) (%) (µg/day) (µg/day)
30 January Ingestion 61 ± 52 86 7.2 120
31 January Ingestion 36 ± 27 74 5.9 70
Excretion 8.1 ± 8.7 110 1.0 21
1 February Ingestion 54 ± 49 91 8.3 120
Excretion 15 ± 8.1 54 8.6 24
5 February Ingestion 82 ± 61 75 7.2 150
6 February Ingestion 43 ± 30 70 13 78
Excretion 10 ± 7.7 74 2.2 21
7 February Ingestion 48 ± 38 80 6.5 94
Excretion 8.6 ± 6.5 75 3.2 16
8 February Ingestion 61 ± 61 100 14 150
Excretion 12 ± 18 150 0.8 38
9 February Ingestion 26 ± 21 81 6.3 53
Excretion 8.4 ± 10 120 2.7 24
10 February Ingestion 20 ± 16 79 6.2 42
Excretion 5.7 ± 7.4 130 1.6 17
12 February Ingestion 26 ± 26 100 3.9 59
13 February Ingestion 24 ± 13 54 6.4 37
Excretion 9.2 ± 13 140 0.8 29
Range Ingestion 20–82 54–100 3.9–13 37–150
Excretion 8.1–15 54–150 0.8–8.6 16–38
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Figure 2. TCAAex versus TCAA concentration in water for all participants for tap water exposure (12 days).
Error bars represent ± 1 SD.TCAA is 100% excreted in urine). We made
the calculation according to:
[1]
where TCAAex(c) is the estimated maximum
potential urinary excretion of TCAA (micro-
grams per day); (TCAA + CH)in is the calcu-
lated ingestion of TCAA + CH (micrograms
per day) for day m; k = 0.693/t1/2; t1/2 is the
excretion half-life estimated for each individ-
ual or the mean of all those measured where
we did not determine an individual t1/2; t in
days is incremented from 0 to m – 1; m is the
integer value nearest to twice the individual
t1/2; and t = 0 corresponds to the day of a
measured TCAAex(m) sample.
The molecular weights of TCAA and
CH differ by only 1%, so we simply added
their mass concentrations for calculations of
potential generation of TCAA in urine.
We assessed time series correspondence
between measured TCAA excretion
[TCAAex(m)] and the calculated upper bound
for excretion [TCAAex(c)] for AD2 and AD6
(Figures 6 and 7, respectively). Figure 6 for
AD2 shows a reasonable correspondence over
the duration of the study. TCAAex(m) was
below TCAAex(c) during the period of tap
water ingestion. During the bottled water
intervention, TCAAex(c) was slightly above or
below TCAAex(m) in the beginning, with mea-
sured excretion levels rising above those pre-
dicted from the residual carryover from the
ingestion of TCAA + CH that occurred before
the bottled water intervention. We also found
this trend in Figure 7 for AD6, where trends
also generally match between TCAAex(m) and
TCAAex(c). Observations for both participants
are consistent with a low-level source of
TCAAex(m) that was independent of the low
levels of TCAAin that occurred with the onset
of the bottled water intervention.
Table 7 summarizes the ratios of
TCAAex to TCAAin, based on comparison of
TCAAex with the (TCAA + CH)in, averaged
over all exposure days, for each participant.
These ratios ranged from 0.12 to 0.67. We
calculated these data using Equation 1,
applying the mean observed half-life of 3
days for the three participants (AD1, AD2,
and AD6) to all other participants and using
Equation 1 to calculate a contribution to
ingestion for the previous 3 days.
The observation that none of the partici-
pants’ TCAAex levels dropped below the
MDL after completion of the DPB-free bot-
tled water intervention needs to be evaluated
in relation to expected levels of TCAAex after
this duration of 2 weeks of TCAA-free water
ingestion. After 5 days on bottled water,
AD1 and AD6 would have been expected to
demonstrate TCAAex levels of 40% and
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Figure 3. TCAA elimination half-life estimation
based on bottled water intervention for AD1 using
creatinine-adjusted TCAA concentration in FMU.
Figure 4. TCAA elimination half-life estimation
based on bottled water intervention for AD2 using
creatinine-adjusted TCAA concentration in FMU.
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Figure 5. TCAA Elimination half-life estimation
based on bottled water intervention for AD6 using
creatinine-adjusted TCAA concentration in FMU.
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Figure 6. Correspondence over the duration of the study of measured TCAA
excretion with half-life–adjusted excretion calculated from TCAA + CH inges-
tion in tap water for AD2.
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Figure 7. Correspondence over the duration of the study of measured TCAA
excretion with half-life–adjusted excretion calculated from TCAA + CH inges-
tion in tap water for AD6.
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tion value, respectively, according to their
half-life estimates. Observed excretion levels
were close to these predicted values, at 40%
and 25%, respectively.
After 14 days on bottled water, AD2
would have been expected to demonstrate
TCAAex levels of 2% of the tap water
“steady state” excretion value according to
the applicable half-life estimate. Observed
excretion levels were substantially higher,
7.5%, than would be predicted from the
residual TCAA excretion washout curve. For
the remaining participants for whom half-
lives could not be determined, we assumed a
half-life of 3 days, leading to an expectation
of finding TCAAex levels of 4% of the tap
water “steady state” excretion values after 14
days on TCAA-free bottled water. The val-
ues observed ranged from 18% to an outlier
value of 270%, with a median of 50%.
These observations also suggest that other
sources of TCAA exposure may have
occurred for some participants, indicating
the need for further investigation of low-
level sources of TCAA from other beverage
or food sources.
The viability of TCAA as a biomarker in
a large-scale epidemiology study is an impor-
tant consideration. Collection of FMU sam-
ples from participants was not a problem
among our volunteers. Weisel et al. (16)
obtained FMU samples from 47 of 49 par-
ticipants of their cross-sectional study, of
which 42 were accepted as valid samples, for
an 86% compliance rate. Likewise, the logis-
tics of FMU and tap water sample collection
are likely manageable. The main issue will be
analytical laboratory capacity and analytical
costs, both of which will be a function of the
analytical method used. Because these
features will likely be limiting constraints on
the feasibility of using FMU samples for
TCAA analysis as a biomarker of DPB expo-
sure, we need to reduce the analytical time
and cost of TCAA analyses (14,30).
Conclusions
In this human exposure and intervention
study, we found considerable inter- and
intraindividual variability in both TCAA
ingestion and excretion. Such variability
seems likely to occur for other individual
DPBs, raising questions about generalizations
of DPB exposures from routine water quality
monitoring data, as has been commonly
done for epidemiologic studies. A major
contribution to the observed variability is the
variability in source and volume of water
consumed for each individual and across all
individuals in the study.
Three study participants demonstrated
an apparent excretion half-life of TCAA
ranging from 2.3 to 3.7 days. This urinary
excretion half-life is considerably longer than
any of the THM biomarkers and is consis-
tent with expectations for TCAA from the
limited literature-based human pharmacoki-
netic data obtained using much higher (by 3
to 4 orders of magnitude) nondrinking water
TCAA exposures.
TCAA can be readily detected in urine
with the analytical methods adapted for this
study. This capability revealed that urinary
TCAA excretion levels were generally low
after prolonged exposure to TCAA-free bot-
tled water. However, the failure of TCAA to
decline to expected low levels, most notably
in those participants with the lowest TCAA
ingestion exposure before the bottled water
intervention, raises concerns about the speci-
ﬁcity of urinary TCAA levels as a marker of
drinking water ingestion.
TCAA in urine was sufﬁciently stable to
allow monitoring in this study with rapid
turnaround of analyses. Urinary sampling for
TCAA is relatively noninvasive, particularly
when FMU samples are used. Although this
study has established that monitoring urinary
TCAA is technically feasible, analytical costs
and analytical resources would likely be a seri-
ous constraint for a larger scale study. Despite
several qualifiers, TCAA remains the most
promising prospect for a biomarker of inges-
tion exposure to DPBs in drinking water.
The study results clearly indicate the
need for more closely controlled exposure
studies to provide greater understanding of
TCAA intake sources, TCAA urinary excre-
tion, and inter- and intraindividual variabil-
ity by avoiding the influence of large
differences in fluid consumption patterns
that occurred in this trial.
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